Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04981795 · ClinicalTrials.gov registry record
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
A clinical trial of Diffuse Large B Cell Lymphoma, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- 100
- Enrollment target
- 20
- Study locations
NCT04981795: Recruiting study of Diffuse Large B Cell Lymphoma, sponsored by Incyte Corporation.
NCT04981795 is a study of Diffuse Large B Cell Lymphoma that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 100 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04981795, a study of Diffuse Large B Cell Lymphoma, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.
Primary Outcome
Incidence and severity of Treatment-emergent serious AEs (SAEs) and AEs (TEAs)
Conditions Studied
Interventions
- DRUG Tafasitamab
Study Locations (20)
North Carolina
- Levine Cancer Institute - Charlotte
- VA Medical Center - Durham - Durham
- Leo Jenkins Cancer Center/ECU School of Medicine - Greenville
Ohio
- Mercy Medical Center - Canton
- Ohio Health Marion Area Physicians - Marion
- Tri County Hematology & Oncology Associates, Inc - Massillon
Alabama
- Alabama Oncology - Birmingham
- Clearview Cancer Institute - Huntsville
Iowa
- McFarland Clinic P.C. - Ames
- Mission Cancer and Blood - Des Moines
Michigan
- University of Michigan Comprehensive Cancer Center Michigan Medicine - Ann Arbor
- Henry Ford Health System - Detroit
New Jersey
- Morristown Medical Center - Morristown
- Rutgers Cancer Institute of New Jersey - New Brunswick
California
- University of California, Irvine Medical Center - Orange
Louisiana
- Tulane Cancer Center - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2026-08-31 |
What NCT04981795 shows while recruiting
NCT04981795 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Tafasitamab is the first listed.
NCT04981795 names 20 study sites across 12 states, led by North Carolina, Ohio, Alabama.
Frequently Asked Questions
What is clinical trial NCT04981795 about?
NCT04981795 is a clinical study titled "realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL". The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combin...
What is the current status of trial NCT04981795?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2021-09-20. Estimated completion is 2026-08-31.
What conditions does trial NCT04981795 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.
What interventions are being tested in trial NCT04981795?
The interventions under investigation include: Tafasitamab (DRUG).
Who is sponsoring clinical trial NCT04981795?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04981795 being conducted?
This trial has 20 study locations across Alabama, California, Iowa, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04981795's enrollment target sits among peer trials
100 42nd of 114 higher than 72 of 114 other Diffuse Large B Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology
RECRUITING
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
RECRUITING · Phase 2
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI